KV Pharmaceutical's Clindesse Cited For Overstating Efficacy Claims By DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Company claimed an 88 percent clinical cure rate in an e-mail alert when studies have shown the highest rate to be 64 percent, notice of violation says.
You may also be interested in...
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.